The neural precursor cell expressed developmentally down-regulated gene 4-2, Nedd4-2, is an epilepsy-associated gene with at least three missense mutations identified in epileptic patients. Nedd4-2 encodes a ubiquitin E3 ligase that has high affinity toward binding and ubiquitinating membrane proteins. It is currently unknown how Nedd4-2 mediates neuronal circuit activity and how its dysfunction leads to seizures or epilepsies. In this study, we provide evidence to show that Nedd4-2 mediates neuronal activity and seizure susceptibility through ubiquitination of GluA1 subunit of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, (AMPAR). Using a mouse model, termed Nedd4-2 andi , in which one of the major forms of Nedd4-2 in the brain is selectively deficient, we found that the spontaneous neuronal activity in Nedd4-2 andi cortical neuron cultures, measured by a multiunit extracellular electrophysiology system, was basally elevated, less responsive to AMPAR activation, and much more sensitive to AMPAR blockade when compared with wild-type cultures. When performing kainic acid-induced seizures in vivo, we showed that elevated seizure susceptibility in Nedd4-2 andi mice was normalized when GluA1 is genetically reduced.
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Introduction
A hyperactive brain circuit is a common abnormality observed in patients with various neurological and psychiatric disorders, including epilepsies (1). Evidence from human genetic studies implicates genes encoding ion channels or their regulators in the etiology of those pathophysiological conditions [1, 2] . Characterizing those genes and their function in regulation of brain circuit activity is likely to reveal novel therapeutic targets for these diseases. One of those genes is the neural precursor cell expressed developmentally downregulated gene 4-like (Nedd4-2) [3] . Nedd4-2, is an epilepsy-associated gene containing at least three missense mutations identified through genomic mutation screening in patients with epilepsy [3] [4] [5] [6] . Nedd4-2 encodes a ubiquitin E3 ligase that belongs to the Nedd4 family of ubiquitin E3 ligases [7] but is the only member encoded by an epilepsy-associated gene [3] . Because of an N-terminal lipid-binding domain, Nedd4-2 has high affinity toward binding and ubiquitinating membrane proteins [8] . Several neuronal membrane substrates of Nedd4-2 have been identified, such as voltage-gated sodium channel Na v 1.6 [9] , voltage-gated potassium channels K v 7/ KCNQ [10] [11] [12] , neurotrophin receptor TrkA [13, 14] and the GluA1 subunit of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) [15] . Our previous work has demonstrated elevated seizure susceptibility in mice when Nedd4-2 is knocked down [16] . However, the mechanisms by which the dysfunction of Nedd4-2 contributes to epileptogenesis are unclear. Presumably wild-type (WT) Nedd4-2 mediates or represses circuit activity by ubiquitinating one or more of its substrates while the epilepsy-associated mutants fail to do so and lead to seizures and/or epilepsies. To test this possibility, we needed to identify the relevant substrate of Nedd4-2 in regulation of neuronal excitability and characterize the effect of epilepsy-associated mutations on substrate recognition.
The AMPAR is a major subtype of ionotropic glutamate receptors and is the most commonly found receptor in the mammalian nervous system [17, 18] . AMPARs are assembled as homo-or hetero-tetramers and are comprised of combinations of GluA1-GluA4 subunits [19] . Each subunit has a non-conserved C-terminal, an intracellular domain that harbors regulatory elements subject to various post-translational modifications such as ubiquitination. All four AMPAR subunits can be ubiquitinated, but only GluA1 ubiquitination has been specifically described upon different activity stimulations [20, 21] . Studies have shown that GluA1 ubiquitination contributes to its internalization [22, 23] . This internalization, part of AMPAR trafficking mechanisms [24] , is critical for synaptic depression as well as homeostatic regulation of synaptic strength [25] [26] [27] [28] . Because GluA1-GluA2 is the predominant AMPAR heteromer [29] , and GluA1 is required for successful trafficking and targeting of GluA2 [30] , we hypothesized that Nedd4-2 is required for limiting GluA1 surface expression and functionality of AMPAR. Because GluA1 levels affect neuronal activity [31] , and dysregulation of AMPARs has been shown to be linked to epilepsy [32, 33] , Nedd4-2 may play a role in affecting neuronal activity, seizures, and/or epilepsy through fine-tuning of AMPARs.
In our current study, we provide in vitro and in vivo evidence to demonstrate GluA1-and AMPAR-dependent elevation of neuronal activity and seizure susceptibility induced by functional insufficiency of Nedd4-2. To our knowledge, our findings provide the first mechanism underlying Nedd4-2-associated circuit hyperactivity and seizures and open up a new avenue for the development of therapeutic strategies to potentially treat epileptic patients who carry Nedd4-2 mutations.
Results

Nedd4-2 mediates spontaneous neuronal and synaptic activity
It is unknown how dysregulation of Nedd4-2 is involved in seizures or epilepsies. To answer this question, we employed a mouse model, Nedd4 -2 andi , in which the long-form (isoform 1)
of Nedd4-2 is selectively deleted due to a spontaneous mutation in exon-2 ( Fig 1A) . Because Nedd4-2 knockout mice are not viable [34] , Nedd4-2 andi serves as an ideal, in vivo knockdown model to study Nedd4-2. To assess the question of whether Nedd4-2 mediates neuronal activity, we employed a multielectrode array (MEA) recording system (S1 Fig) to record extracellular spontaneous spikes of electrical activity in primary cortical neuron cultures prepared from WT or Nedd4-2 andi mice. As shown in Fig 1B, (Fig 1C) . These data indicate that spontaneous neuronal activity is basally elevated in Nedd4-2 andi cortical cultures.
To determine whether elevated spontaneous neuronal activity in Nedd4-2 andi cultures is accompanied by altered synaptic transmission, we performed whole-cell patch-clamp recording to obtain miniature excitatory post-synaptic current (mEPSC) from WT or Nedd4-2 andi cortical neuron cultures. As shown in Fig 1D , Nedd4-2 andi neurons exhibit elevation of both mEPSC amplitude and frequency when compared to WT neurons. These data suggest that Nedd4-2 likely mediates both pre-and post-synaptic properties, and the elevation of spontaneous neuronal activity observed in Nedd4-2 andi cortical cultures (Fig 1C) is likely contributed by multiple factors.
Nedd4-2 mediates AMPAR-dependent spontaneous neuronal activity
We previously identified the GluA1 subunit of AMPAR as a substrate of Nedd4-2 [15] . We therefore asked whether AMPAR mediates spontaneous neuronal activity and whether it is responsible for the hyperactivity observed in Nedd4-2 andi cultures. An AMPAR agonist, AMPA (1 μM), was applied to determine how spontaneous neuronal activity was affected when AMPAR was activated. MEA recordings from WT cultures before and after AMPA treatment for 15 min indicated elevated spontaneous spike frequency (Fig 2A 1 and 2A 3 ) suggesting that spontaneous neuronal activity can be modulated by AMPARs. The same treatment produced significant, but smaller, effects on Nedd4-2 andi cultures (Fig 2A 2 and 2A 3 ; Significant interaction between treatment and genotype was detected, p<0.05.). The average of spontaneous spike amplitude ( Fig 2B) and electrode burst activity did not differ after AMPA treatment for either genotype (S2A Fig) . These data suggest that Nedd4-2 contributes to the elevation of spontaneous neuronal activity, particularly spontaneous spike frequency, when the AMPAR is activated.
We then asked whether Nedd4-2 andi cultures respond differently when AMPARs are pharmacologically inhibited. We employed a specific AMPAR antagonist, NBQX (2 μM), and again recorded the spontaneous neuronal activity before and after a 15-min treatment. As shown in Fig 3A, NBQX slightly, but not significantly, reduced spontaneous spike frequency in WT cultures, while NBQX significantly reduced spike frequency in Nedd4-2 andi cultures (Significant interaction between treatment and genotype was detected, p<0.05.). Again, average spontaneous spike amplitude did not differ between either treatments or genotypes ( Fig  3B) . Interestingly, we observed elevated burst activity without changes in interburst interval (IBI) after NBQX treatment (S2B Fig) , which was also observed in another study [35] . Although we suspect the lack of changes in IBI is potentially because NBQX was applied acutely, we did not pursue further experiments with prolonged treatments since our data suggest that NBQX-induced burst activity is independent of Nedd4-2 (S2B 1 and S2B 2 Fig) . We previously showed elevated synchrony of spontaneous neuronal activity in Nedd4-2 andi cultures [16] . Elevation of synchronized activity indicates potentially elevated network activity. To determine whether AMPAR is involved in this phenomenon, we analyzed the synchrony index in WT and Nedd4-2 andi cultures treated with either AMPA or NBQX. As shown, although AMPA treatment elicits some effect toward elevation of synchrony, no difference was observed between genotypes. NBQX, on the other hand, produces no effect on synchrony in either WT or Nedd4-2 andi cultures (S3 Fig). These results suggest that, although prolonged stimulation of AMPAR might further elevate the synchrony of neuronal activity, the effect is unlikely to be Nedd4-2-dependent. Furthermore, AMPAR is also unlikely to be responsible for basally elevated synchrony when Nedd4-2 is compromised [16] since NBQX exerts no effect. Therefore, whether and how Nedd4-2 mediates synchrony of spontaneous neuronal activity or other network activity, such as network spikes and bursts, through other substrates would be an important future direction. 4A) . We then determined seizure susceptibility in these mice by intraperitoneal injections of kainic acid. Four-week-old mice were injected with kainic acid (15, 30, or 60 mg/kg) as done in our previous study [16] . Behavioral seizures were monitored and scored during a 1-hr 
Nedd4-2 ubiquitinates GluA1 at lysine-868 and mediates its surface expression
Our data suggest that impaired GluA1 ubiquitination may be responsible for Nedd4-2-mediated seizure and/or epilepsies. To test this hypothesis, we sought to characterize the functional consequence of GluA1 ubiquitination by Nedd4-2. We first attempted to map the Nedd4-2-ubiquitinated residues of GluA1 as ubiquitination at different residues may affect the function of GluA1 differently [20, 21] . We employed human embryonic kidney (HEK) cells because they do not express a detectable level of GluA1 or Nedd4-2 endogenously (S4 Fig) .
There are four lysine residues (K813, K819, K822, and K868) located on the carboxyl-terminal, intracellular domain of GluA1 ( Fig 5A) [21] [22] [23] . As reported previously, mutating all four residues completely abolishes GluA1 ubiquitination; this rules out other lysine residues as targets [21] . Accordingly, WT Nedd4-2 was then co-transfected with WT GluA1 or mutant GluA1s in which each lysine was replaced by arginine (R) at each individual site (K813R, K819R, K822R and K868R) or all four lysine residues together were mutated to R (4KR). As shown in Fig 5B, the GluA1 with either K868R or all four lysine residues mutated to arginine (4KR) showed significantly reduced ubiquitination when co-expressed with Nedd4-2. A trend toward reduced ubiquitination is also observed when GluA1 carries K822R, suggesting a potential alternative residue for Nedd4-2-mediated ubiquitination. In summary, these results suggest that K868 is the most critical residue ubiquitinated by Nedd4-2. GluA1 ubiquitination at K868 has been shown to affect its surface expression [22, 23] . To determine whether Nedd4-2 mediates surface expression of GluA1, we labeled surface proteins with biotin in WT or Nedd4-2 andi cortical neuron cultures followed by purification of biotinylated proteins with streptavidin beads. As shown in Fig 5C , Nedd4-2 andi cultures indeed exhibited elevated surface GluA1 when compared with WT cultures. N-cadherin serves as a control and did not differ between WT or Nedd4-2 andi cultures. These results confirm the role of Nedd4-2 in limiting GluA1 surface expression. Because elevated surface GluA1 level has been linked to enhanced seizure susceptibility [37, 38] , our findings further support our hypothesis that altered GluA1 ubiquitination contributes to Nedd4-2-associated seizures and/ or epilepsies.
Three epilepsy-associated missense mutations reduce Nedd4-2-mediated GluA1 ubiquitination
There are three epilepsy-associated missense mutations of Nedd4-2 (S233L, E271A, and H515P) identified in patients with epilepsies [4, 5] . Based on our findings, we aimed to test the hypothesis that one or more of these mutations could disrupt GluA1 ubiquitination. To avoid potential inference from other neuronal E3 ligases for GluA1 [39, 40] , we applied reconstitutive systems to determine GluA1 ubiquitination using either HEK cells or in vitro ubiquitination. When using HEK cells co-transfected with GluA1 and Nedd4-2, we found that GluA1 is less ubiquitinated when co-expressed with any of the Nedd4-2 mutants in comparison to WT Nedd4-2 ( Fig 6A and S5 Fig) . When in vitro ubiquitination was performed using recombinant full-length GluA1 with WT or any of the expressed Nedd4-2 mutants (partially purified from HEK cells), we also found that in comparison to WT Nedd4-2, all three mutant Nedd4-2s exhibited reduced ability to ubiquitinate GluA1 in vitro (Fig 6B) . Previously we showed that Nedd4-2-mediated-GluA1 ubiquitination leads to degradation of GluA1 [15] . To determine whether mutant Nedd4-2s fail to degrade GluA1, HEK cells were Western blots of GluA1, N-cadherin, and Actin from WT or Nedd4-2 andi cortical neuron cultures. Proteins from total lysate or after surface biotinylation were as indicated (n = 3, one-sample t-test was performed after normalization to WT groups). For all experiments, data are represented as mean ± SEM with *p<0.05, **p<0.01. co-transfected with GluA1 and WT or mutant Nedd4-2. Using cycloheximide (100 μg/ml) to inhibit protein translation and follow protein degradation, significant GluA1 down-regulation is only observed when co-expressed with WT Nedd4-2 but not with any of the mutant Nedd4-2s (Fig 6C) . Slightly enhanced levels of GluA1 or Nedd4-2 after cycloheximide treatment were observed in some groups after normalization with the internal control Tubulin. This is due to a lower turnover rate of GluA1 or Nedd4-2 than that of Tubulin when cells were transfected with mutant Nedd4-2s. To strengthen the idea that GluA1 degradation is altered when coexpressed with mutant Nedd4-2s, HEK cells co-transfected with GluA1 and WT or mutant Nedd4-2 were treated with proteasome inhibitor MG132 (10 μM) ( S6 Fig). GluA1 significantly accumulates when co-expressed with WT Nedd4-2, but not with any of the mutant Nedd4-2s, after MG132 treatment. Altogether, our data suggest that all three missense mutations disrupt Nedd4-2-mediated GluA1 ubiquitination and degradation.
Three epilepsy-associated missense mutations of Nedd4-2 disrupt 14-3-3-facilitated GluA1 ubiquitination
When expressing WT or mutant Nedd4-2s in HEK cells, it was observed that the mutant Nedd4-2s exhibited increased basal levels and reduced degradation when compared with WT Nedd4-2 ( Fig 6C 3 and S6 Fig) , suggesting enhanced stability. Because Nedd4-2 can self-ubiquitinate, the reduced down-regulation of both GluA1 and Nedd4-2 suggests that these missense mutations most likely affect the general ubiquitination process mediated by Nedd4-2 [41, 42] . Furthermore, all three mutations are located on or near one of the three protein-protein interaction domains (WW domain) in Nedd4-2 (S7 Fig), suggesting potentially altered interaction with its interacting proteins. To test this possibility, we studied the adaptor protein 14-3-3, which directly interacts with Nedd4-2 and has been shown to mediate Nedd4-2's substrate recognition [43] [44] [45] . We first aimed to determine whether 14-3-3 mediates Nedd4-2-mediated GluA1 ubiquitination. In vitro ubiquitination using recombinant GluA1 and Nedd4-2 yielded some GluA1 ubiquitination (Fig 7A 1 , lane 1) . Remarkably, in the presence of recombinant 14-3-3ε, one of the 14-3-3 isoforms known to interact with Nedd4-2 [46] , GluA1 ubiquitination was significantly enhanced (Fig 7A 1 , lane 2) . To validate the role of 14-3-3, a peptide-based general 14-3-3 inhibitor, R18 trifluoroacetate (R18; 0.025 mg/ml), which is known to disrupt the interaction between 14-3-3 and its binding partners, was used [47] [48] [49] . As predicted, R18 reduced GluA1 ubiquitination to a level similar to Nedd4-2 alone (Fig 7A 1 , lane 4) . For controls, the same reactions in the absence of either Nedd4-2 or ubiquitin showed nearly undetectable GluA1 ubiquitination ( Fig  7A 1 , lanes 5-8) . These data suggest that, while Nedd4-2 is capable of ubiquitinating GluA1 in the absence of 14-3-3, 14-3-3 significantly facilitates this ubiquitination.
We then asked whether reduced GluA1 ubiquitination by epilepsy-associated missense mutations of Nedd4-2 occurred through altered interactions with 14-3-3. WT or mutant Nedd4-2 was transfected into HEK cells. Co-immunoprecipitation showed that all three mutants have reduced interactions with endogenous 14-3-3 in HEK cells (Fig 7B) . Similar results were obtained when using recombinant 14-3-3ε to immunoprecipitate WT or mutant Nedd4-2 expressed in HEK cells (S8 Fig). To determine whether the Nedd4-2 mutants fail to respond to 14-3-3 when ubiquitinating GluA1, in vitro ubiquitination using recombinant GluA1 and WT or mutant Nedd4-2 partially purified from HEK cells was performed. While WT Nedd4-2 strongly ubiquitinated GluA1 and responded to additional 14-3-3ε with further GluA1 ubiquitination, all of the mutant Nedd4-2s failed to do so (Fig 7C) . Because the level of 14-3-3 does not seem to be regulated by Nedd4-2 ( S9 Fig), our results suggest that the epilepsy-associated missense mutations of Nedd4-2 disrupt GluA1 ubiquitination, at least partially through reduced interaction with 14-3-3.
Three epilepsy-associated missense mutations of Nedd4-2 fail to regulate surface GluA1 and spontaneous neuronal activity Because the epilepsy-associated missense mutations of Nedd4-2 disrupt GluA1 ubiquitination and degradation, we hypothesize that these mutations fail to mediate surface GluA1 and spontaneous neuronal activity. To this end, we performed surface protein biotinylation to obtain and measure surface GluA1 from WT cortical neuron cultures lentivirally transduced with WT or mutant Nedd4-2 for 5 days. Surprisingly, no significant effect was observed (S10 Fig). We suspect that the level of Nedd4-2 during early development might reach a threshold in WT cultures, and therefore expression of additional Nedd4-2 fails to elicit significant effects. Furthermore, because mutant Nedd4-2s exhibit significantly reduced affinity toward interacting with 14-3-3 and therefore GluA1 (Figs 6 and 7) , they might not be dominant-negative, at least in the context of GluA1 ubiquitination. The endogenous Nedd4-2 in WT cultures potentially dominates even in the presence of mutant Nedd4-2s. Therefore, to determine the effects of mutant Nedd4-2s without the interference from endogenous Nedd4-2, we repeated this experiment in Nedd4-2 andi cortical neuron cultures. Using Nedd4-2 andi cultures possesses the advantage of studying the behavior of mutant Nedd4-2s while minimizing the concern of overexpression. As shown in Fig 8A , WT Nedd4-2 significantly reduced total and surface GluA1 in Nedd4-2 andi cultures while all three mutant Nedd4-2s showed no effect. When expressing WT Nedd4-2 or any of the mutant Nedd4-2s in Nedd4-2 andi cortical neuron cultures for 5 days, we found that the cultures transduced with WT Nedd4-2 showed significantly lower spontaneous spike frequency when compared with untransduced cultures or cultures transduced with any of the mutant Nedd4-2s ( Fig 8B 1 and 8B 2 ) . The average spontaneous spike amplitude did not differ between transduced and untransduced cultures. Altogether, our data showed that the three epilepsy-associated missense mutations of Nedd4-2 disrupt the ability to regulate surface GluA1 and spontaneous neuronal activity.
Discussion
In this study, we present evidence to show that neuronal hyperactivity in vitro and increased seizure susceptibility in vivo associated with Nedd4-2 dysfunction are modulated by altered GluA1 and AMPAR signaling. These findings are further supported by the data showing that three epilepsy-associated missense mutations of Nedd4-2 partially, but significantly, disrupted GluA1 ubiquitination through reduced interaction with the adaptor protein 14-3-3. All mutant Nedd4-2s retain partial function toward ubiquitinating GluA1, reflecting the fact that the mutations were located on or near protein-protein interaction domains but not the lipid-binding or catalytic HECT (Homologous to the E6-AP Carboxyl Terminus) domain. Nevertheless, this is the first report that demonstrates a mechanism to explain Nedd4-2-dependent epilepsy in patients. Although the mutations of Nedd4-2 increase its stability, which is different from the in vivo knockdown mouse model we used (Nedd4-2 andi mice), we showed that the reduction of Nedd4-2 and the mutations each reduce the ability of Nedd4-2 to ubiquitinate GluA1. Furthermore, because our data showed that genetic reduction of GluA1 normalized the seizure response in Nedd4-2 andi mice, it suggests that inhibition of AMPARs might be a suitable treatment plan for Nedd4-2-associated epilepsy. One of the antagonists of AMPAR, Perampanel, has been approved to clinically reduce partial-onset seizures with or without secondary generalized seizures in epileptic patients [50] [51] [52] . Such medication might therefore be specifically useful for epilepsy patients who carry mutations in Nedd4-2. A future study on Perampanel will be very important to determine whether and to what the extent Nedd4-2-associated seizures and/or epilepsy can be ameliorated. We used Nedd4-2 andi mice, in which the long form of Nedd4-2 is disrupted, to study Nedd4-2. Because Nedd4-2 knockout mice exhibit perinatal lethality [34] , Nedd4-2 andi mice serve as an ideal model to study Nedd4-2 in vivo. However, another question is thus raised regarding the differential contribution of long versus short form of Nedd4-2 to the regulation of spontaneous neuronal activity and brain circuit excitability. The short form of Nedd4-2, which lacks an Nterminal C2 domain (S7 Fig), has also been identified in humans [53, 54] . Indirect evidence has suggested that the C2 domain mediates membrane-targeting of Nedd4-2 [8] . The C2-containing (long) and C2-lacking (short) isoforms therefore target different intracellular locations and substrate pools [8] . Currently, it is unclear whether the short form of Nedd4-2 exhibits similar affinity toward binding to and ubiquitinating GluA1. If it does, the question arises as to whether epilepsy-associated mutations affect the function of short form Nedd4-2 in a similar manner as to the long form of Nedd4-2. If it does not, the second question is whether the short form serves as a dominant-negative Nedd4-2 to sequester interacting or signaling molecules to affect the functions of the long form of Nedd4-2. Because single-nucleotide polymorphisms (SNPs) in human Nedd4-2 lead to differential expression of these isoforms, examining the functional differences of these isoforms may increase our understanding of neuronal plasticity and associated seizure susceptibility in different populations [53, 54] . In the adult brain, the AMPAR has been shown to mediate the majority of excitatory synaptic transmission with GluA1 being one of the major subunits [55] . Activity-mediated changes in the numbers and properties of GluA1/AMPAR are essential for excitatory synapse development and synaptic plasticity. Ubiquitination of GluA1 has been linked to AMPAR surface expression and trafficking, which subsequently may affect many synaptic plasticity mechanisms, such as homeostatic synaptic scaling and synaptic depression [21-23, 56, 57] . We previously demonstrated that Nedd4-2 mediates GluA1 ubiquitination upon chronic neuronal activity stimulation, suggesting a potential role of Nedd4-2 in homeostatic synaptic downscaling [15] . Whether Nedd4-2 participates in other synaptic plasticity mechanisms is unknown. One speculation would be that because Nedd4-2 functions to limit the amount of surface GluA1 as seen in Fig 5C , neuronal activity that mediates depression or elimination of excitatory synapses might induce Nedd4-2-mediated GluA1 ubiquitination. We recently found that the expression of Nedd4-2 is modulated by another ubiquitin E3 ligase murine double minute-2 (Mdm2) and its downstream effector tumor suppressor p53 [15] . Mdm2 is known to be crucial for activity-dependent synapse elimination [58] , which is crucial for brain circuit development and maturation. Activation of Mdm2-p53 signaling and Nedd4-2 expression might therefore contribute to elimination of excitatory synapses. Activation of Mdm2-p53 signaling and Nedd4-2 expression might therefore contribute to elimination of excitatory synapses. Further studies are required to delineate the broader effects of Nedd4-2.
In addition to GluA1, other neuronal substrates of Nedd4-2 potentially involved in neuronal activity regulation are voltage-gated sodium channels Na v 1.6 and voltage-gated potassium channels K v 7.3/KCNQ3 [9] [10] [11] [12] . These two substrates are both crucial to modulating action potential firing and intrinsic excitability. Although our data showed that GluA1 mediates Nedd4-2-associated neuronal hyperactivity and seizures in mice, it does not rule out the potential contributions of Na v 1.6 and K v 7.3/KCNQ3 in Nedd4-2-associated brain circuit excitability. Our data also suggest that presynaptic defects are potentially involved in the neuronal deficits associated with Nedd4-2 (Fig 1D) . Multiple substrates of Nedd4 family members are known to mediate presynaptic vesicle release and activity, including α-synuclein [59] [60] [61] and tyrosine kinase A receptors [13, 14, 62] . Altered ubiquitination of these substrates when Nedd4-2's function is compromised could contribute to aberrant synaptic transmission. The ubiquitination status, expression level, and subcellular distribution of Nedd4-2's other substrates are pending further investigation to obtain the full picture of synaptic abnormality and excitability caused by pathogenic functions of mutant Nedd4-2s. As we described previously, future studies are expected to elucidate broader effects of Nedd4-2 and provide better understanding of this important, yet underdeveloped, molecule in the central nervous system.
Materials and methods
Ethics statement
All experiments using animal data followed the guidelines of Animal Care and Use provided by the Illinois Institutional Animal Care and Use Committee (IACUC) and the guidelines of the Euthanasia of Animals provided by the American Veterinary Medical Association (AVMA) to minimize animal suffering and the number of animals used. This study was performed under an approved IACUC animal protocol of University of Illinois at Urbana-Champaign (#14139 to N.-P. Tsai.)
Animals and primary cortical neuron cultures
The Nedd4-2 andi mice, GluA1 knockout mice and WT control mice were obtained from
The Jackson Laboratory. Primary cortical neuron cultures were made from p0-p1 mice as described previously [58] and maintained in NeuralQ basal medium (Sigma) supplemented with 1X B27 supplement (Invitrogen), 1X GlutaMax (final concentration at 2 mM; Invitrogen), and Cytosine β-D-arabinofuranoside (AraC, final concentration at 2 μM; Sigma). The medium was changed 50% on DIV 2 and every 3 days thereafter.
Reagents and constructs
Dimethyl sulfoxide (DMSO) was from Fisher Scientific. AMPA was from Cayman Chemical and NBQX was from Alomone Labs. Recombinant GluA1 and 14-3-3ε were from Origene. Recombinant Nedd4-2 was from Abnova. R18 was from Sigma-Aldrich. Cycloheximide, poly-D-lysine and Protein A/G beads were from Santa Cruz Biotechnology. The antibodies used in this study were purchased from Santa Cruz Biotechnology (anti-α-Tubulin), Cell Signaling (anti-Nedd4-2, anti-pan-14-3-3, anti-N-cadherin and anti-Ubiquitin), Millipore (anti-GluA1), Abcam (anti-MAP2), Thermo Scientific (anti-HA) and GenScript Corporation (anti-Gapdh).
The epilepsy-associated mutations were generated using site-directed mutagenesis reagent (Agilent) to introduce mutations into pCI-HA-Nedd4-2 [15] . The primers used are as below. S233L: 5'-GGACGTGTCCTCGGAGTTGGACAATAACATCAGAC-3', 5'-GTCTGATGTTATTGTCCAACTCCGAGGACACGTCC-3'; E271A: 5'-GGGCGGGGATGTCCCCGCGCCTTGGGAGACCATTTC-3', 5'-GAAATGGTCTCCCAAGGCGCGGGGACATCCCCGCCC-3'; H515P: 5'-CGTTTGAAATTTCCAGTACCTATGCGGTCAAAGACATC-3', 5'-GATGTCTTTGACCGCATAGGTACTGGAAATTTCAAACG-3'.
Surface protein biotinylation
After washing cultured cells with PBS three times, 0.1 mg LLC NHS-LC-BIOTIN (from Apexbio Technology) was added to cultures for 30 min. at room temperature. At the end of the reaction, cultures were washed with PBS three times. The cell were harvested and lysed in an IP buffer (50 mM Tris, pH 7.4, 120 mM NaCl, 0.5% Nonidet P-40) followed by purification using Magnetic Streptavidin Beads (from Cell Signaling).
Transfection, immunoprecipitation and western blotting
HEK cells were transfected using Lipofectamine 3000 (Invitrogen). Primary neuron cultures were transduced using lentivirus. WT and mutant Nedd4-2s were sub-cloned into Lenti-CMV-GFP-2A-Puro Vector (from Applied Biological Materials). Lentivirus was produced in HEK cells as described previously [58] . For immunoprecipitation (IP), cell lysates were obtained by sonicating pelleted cells in IP buffer. Eighty μg of total protein or protein mixtures after in vitro ubiquitination was incubated 2 hours at 4˚C with 0.5 μg primary antibodies. Protein A/G agarose beads were added for another hour followed by washing with IP buffer three times. For western blotting, after SDS-PAGE, the gel was transferred onto a polyvinylidene fluoride membrane. After blocking with 1% Bovine Serum Albumin in TBST buffer (20 mM Tris pH 7.5, 150 mM NaCl, 0.1% Tween-20), the membrane was incubated with primary antibody overnight at 4˚C, followed by three 10-min washings with TBST buffer. The membrane was then incubated with an HRPconjugated secondary antibody (from Santa Cruz Biotechnology) for 1 hour at room temperature, followed by another three 10-min washings. Finally, the membrane was developed with an ECL Chemiluminescent Reagent [15] . All the western blot results were semi-quantitatively normalized to the control groups before statistical analysis.
In vitro ubiquitination
HA-Ub (Boston Biochem), Ubiquitin Activating Enzyme (UBE1) (Boston Biochem) and UbcH5b/UBE2D2 (Boston Biochem) were obtained. Recombinant WT Nedd4-2 was obtained from Abcam. When HA-tagged WT or mutant Nedd4-2s were produced in HEK cells, 250 μg of total protein lysates were subjected to immunoprecipitation with anti-HA antibody to partially purify HA-tagged Nedd4-2s. Recombinant GluA1 (Origene) was used as substrate for in vitro ubiquitination with recombinant Nedd4-2 (Fig 7A) or Nedd4-2s obtained from transfected HEK cells ( Figs 6B and 7C ) following a protocol previously described [63] . Recombinant 14-3-3ε was obtained from Origene.
MEA recording
Each MEA plate was coated with poly-D-lysine for 30 minutes and plated with 2x10 5 cells counted using a hemocytometer. Recordings were done at DIV 13-14 ( Figs 1, 2 and 3 ) or DIV 9 and DIV 14 (Fig 8) in the same culture medium using an Axion Muse 64-channel system in single well MEAs (M64-GL1-30Pt200, Axion Biosystems) inside a 5% CO 2 , 37˚C incubator. Field potentials (voltage) at each electrode relative to the ground electrode were recorded with a sampling rate of 25 kHz. Right before a recording, if an electrode channel displays excessive "noise" (>10 μV) that channel is grounded for the entirety of the recording to avoid interference with other channels [64] . After 30 min of baseline recording, the MEA was treated with the drugs specified and recorded for another 30 min. Due to changes in network activity caused by physical movement of the MEA, only the last 15 min of each recording were used in data analyses. AxIS software (Axion Biosystems) was used for the extraction of spikes (i.e. action potentials) from the raw electrical signal obtained from the Axion Muse system. After filtering, a threshold of ±7 standard deviations was independently set for each channel; activity exceeding this threshold was counted as a spike. Only MEAs with more than 2,000 spikes during the last 15 minutes of recording were included for data analysis [16, 65] . The total spikes obtained from each MEA culture was normalized to the number of electrodes, as described in a previous study [66] . The settings for burst detection in each electrode were a minimum of 5 spikes with a maximum inter-spike interval of 0.1 sec as described previously [16] . The burst duration, number of spikes per burst, and interburst interval were analyzed by AxIS software. Synchrony index was also computed through AxIS software, based on a published algorithm [67] as we conducted previously [16] , by taking the cross-correlation between any two spike trains, removing the portions of the cross-correlogram that are contributed by the auto-correlations of each spike train, and reducing the distribution to a single metric.
To ensure consistency when acquiring MEA data, all the experiment procedures, including the animal dissection, cell counting and plating, medium changing, and recordings are conducted by the same individual in each experiment. Throughout culture maturation and before recording, each MEA is visually inspected under the microscope and any MEA with poor growth or a patchy network is excluded. Recordings of each experiment were alternate between genotypes. For all before and after drug treatment comparisons, to minimize the variability between cultures, the recording from each MEA culture after treatment was compared to the baseline recording from that same culture.
Immunocytochemistry
Immunocytochemistry was done as previously described [68] . In brief, primary neurons grown on poly-D-lysine coated coverslips were fixed at DIV 14 with ice-cold buffer (4% paraformaldehyde and 5% sucrose in PBS). After washing and permeabilization with an additional incubation with 0.5% Triton X-100 in PBS for 5 min, an incubation with anti-MAP2 antibody was performed for 4 hours. After washing three times with PBS, fluorescence-conjugated secondary antibodies were applied to the cells at room temperature for 1 hour. After additionally washing the cells three times with PBS, the coverslips were mounted and observed on Zeiss LSM 700 Confocal Microscope.
Seizure susceptibility
Male mice at age 4-weeks old were intraperitoneally injected with kainic acid, prepared in saline solution (Hannas Pharmaceutical), at doses of 15, 30, or 60 mg/kg. The total injection volume was kept close to 0.15 ml. After injection, mice were closely observed in real time for 1 hour. The intensity of seizure was assessed by Racine's scoring system [69] . To clearly determine seizure susceptibility, only stage 4 (rearing) and stage 5 (rearing and falling) were considered positive for seizures, as previously performed [16, 70] 
Statistical analysis
ANOVA with post-hoc Tukey HSD (Honest Significant Differences) test was used for multiple comparisons between treatments or genotypes. Student's t-test was used for analyzing spontaneous neuronal activity in Fig 1B and 1C , and mEPSC data in Fig 1D. One-sample t-test was used when experimental groups were normalized to control groups, such as western blotting in Fig 5C . Each "n" indicates an independent culture. Differences are considered significant at the level of p < 0.05. Investigation: JZ KYL KAJ NPT.
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